The Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC) is a group of scientific researchers who conduct meta-analyses of the worldwide epidemiological evidence on risk factors for breast cancer in women. It formed in 1992.[1] Their earliest publications were a 1996 meta-analysis of 54 studies on hormonal birth control and breast cancer risk[2] and a 1997 meta-analysis of 51 studies on menopausal hormone therapy and breast cancer risk.[3] One of their recent publications was a 2019 meta-analysis of menopausal hormone therapy and breast cancer risk based on type and timing of therapy.[1] In 2012, the group concluded in a meta-analysis of 117 studies that the incidence of breast cancer was increased by each year younger at menarche and each year older at menopause.[4]
References
edit- ^ a b Collaborative Group on Hormonal Factors in Breast Cancer (September 2019). "Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence". Lancet. 394 (10204): 1159–1168. doi:10.1016/S0140-6736(19)31709-X. PMC 6891893. PMID 31474332.
- ^ Collaborative Group on Hormonal Factors in Breast Cancer (June 1996). "Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies" (PDF). Lancet. 347 (9017): 1713–27. doi:10.1016/s0140-6736(96)90806-5. PMID 8656904. S2CID 36136756.
- ^ "Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer". The Lancet. 350 (9084): 1047–1059. 1997. doi:10.1016/S0140-6736(97)08233-0. ISSN 0140-6736. S2CID 54389746.
- ^ Collaborative Group on Hormonal Factors in Breast Cancer (2012). "Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies". The Lancet Oncology. 13 (11): 1141–1151. doi:10.1016/S1470-2045(12)70425-4. ISSN 1470-2045. PMC 3488186. PMID 23084519.